MBNL1 and myotonic dystrophy: Previously, we applied a similar strategy in a mouse model of myotonic dystrophy, in which ASO blockers targeting CUGexp corrected the alternative splicing of hundreds of genes due to the release of MBNLs (muscleblind-like splicing regulators) from pathogenic sequestration on rCUGexp40,41.